Viking Therapeutics has captured significant investor attention following the release of new clinical data for its obesity treatment, VK2735. The biopharmaceutical company is presenting these compelling findings at two major medical conferences: ObesityWeek® 2025 and the upcoming American Heart Association (AHA) Scientific Sessions.
Ambitious Clinical Development Roadmap
The company is utilizing these conferences to outline its strategy for VK2735’s advanced clinical development. The ongoing Phase 3 programs, VANQUISH-1 and VANQUISH-2, are central to this plan. Viking Therapeutics has set an ambitious timeline, aiming to complete patient recruitment for the VANQUISH-1 trial before the end of this year. This aggressive schedule highlights the company’s confidence in its flagship product.
Compelling Efficacy Metrics from Phase 2 Study
Fresh analyses from the 13-week Phase 2 VENTURE study demonstrate that VK2735 delivers substantial benefits beyond weight loss, significantly improving key cardiometabolic health markers. These results substantially strengthen the drug’s clinical profile, a critical factor for its continued progression through the development pipeline.
Should investors sell immediately? Or is it worth buying Viking Therapeutics?
The specific data points present a powerful case for the treatment’s efficacy:
- Reversal of Prediabetes: 78% of patients treated with VK2735 saw their prediabetes reverse, compared to just 29% in the placebo group.
- Resolution of Metabolic Syndrome: 68% of patients who had metabolic syndrome no longer met the diagnostic criteria for the condition after treatment, versus 38% in the placebo arm.
- Sustained Weight Reduction: Previously reported weight reductions of up to 14.7% were maintained, with no evidence of a plateau effect after the full 13-week period.
This collection of data suggests VK2735 could achieve a best-in-class profile within the highly competitive market for GLP-1/GIP agonists. The positive investor sentiment is directly reflected in a notable uptick for Viking Therapeutics shares.
Ad
Viking Therapeutics Stock: Buy or Sell?! New Viking Therapeutics Analysis from November 7 delivers the answer:
The latest Viking Therapeutics figures speak for themselves: Urgent action needed for Viking Therapeutics investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from November 7.
Viking Therapeutics: Buy or sell? Read more here...
